Stifel Financial (SF) appointed Jonathan Siegmann as Managing Director of Equity Research, covering the aerospace and defense industry. He will be based in the firm’s Boston office. Most ...

A Finra arbitration panel has ordered Stifel Financial Corp. to pay about $132 million in damages for allegedly misleading investors by pitching a product as less risky than it actually was ...

(Reuters) - Stifel Financial was ordered by a Financial Industry Regulatory Authority arbitration panel to pay a family $132.5 million for misrepresenting the risk of complex structured notes ...

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on ATS Corporation (ATS – Research Report) today and set a price target of C$52.00. The company’s shares opened today at C$37.47 ...

That conduct by Stifel included: overconcentrating the clients’ accounts in structured notes, as well as limited industries; disregarding the clients’ investment philosophy; and placing the ...

The panel said Stifel had "actual knowledge of the wrongfulness of the conduct and the high probability that injury or damage" would result from overconcentration of the claimants' accounts in ...

Stifel has been hit with a large penalty in an arbitration case stemming from a broker’s structured-notes strategy that has resulted in more than a dozen investor complaints.

(Reuters) - Stifel Financial was ordered by a Financial Industry Regulatory Authority arbitration panel to pay a family $132.5 million for misrepresenting the risk of complex structured notes, causing ...

On Friday, Stifel analysts highlighted a selection of Med-Tech stocks that present favorable risk/reward opportunities, despite the industry’s current challenges with back-end weighted guidance ...

Stifel Financial Corporation (Symbol: SF) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further ...

As of March 4, 2025, the average one-year price target for Danaher is $271.30/share. The forecasts range from a low of $242.40 to a high of $325.50. The average price target represents an increase ...

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is ...